PL1934243T3 - Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych - Google Patents

Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Info

Publication number
PL1934243T3
PL1934243T3 PL06803140T PL06803140T PL1934243T3 PL 1934243 T3 PL1934243 T3 PL 1934243T3 PL 06803140 T PL06803140 T PL 06803140T PL 06803140 T PL06803140 T PL 06803140T PL 1934243 T3 PL1934243 T3 PL 1934243T3
Authority
PL
Poland
Prior art keywords
formula
compound
preparation
ring
closing metathesis
Prior art date
Application number
PL06803140T
Other languages
English (en)
Inventor
Chutian Shu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL1934243T3 publication Critical patent/PL1934243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL06803140T 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych PL1934243T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71553405P 2005-09-09 2005-09-09
PCT/US2006/034921 WO2007030656A1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides
EP06803140A EP1934243B1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides

Publications (1)

Publication Number Publication Date
PL1934243T3 true PL1934243T3 (pl) 2011-10-31

Family

ID=37549189

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06803140T PL1934243T3 (pl) 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Country Status (9)

Country Link
US (1) US7951773B2 (pl)
EP (1) EP1934243B1 (pl)
JP (1) JP5190364B2 (pl)
AT (1) ATE510846T1 (pl)
CA (1) CA2621360C (pl)
DK (1) DK1934243T3 (pl)
ES (1) ES2364426T3 (pl)
PL (1) PL1934243T3 (pl)
WO (1) WO2007030656A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
JP5517614B2 (ja) 2006-07-13 2014-06-11 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス複製阻害剤としての４−アミノ−４−オキソブタノイルペプチド類
WO2008106130A2 (en) 2007-02-26 2008-09-04 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US8193346B2 (en) * 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
NZ587133A (en) 2008-02-04 2012-10-26 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitor compounds for treating an HCV infection
CA2722867A1 (en) * 2008-05-09 2009-11-12 Boehringer Ingelheim International Gmbh A method for preparing macrocycles
MX2011000789A (es) * 2008-08-07 2011-02-24 Hoffmann La Roche Proceso para la preparacion de un macrociclo.
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
ES2527166T3 (es) 2008-12-10 2015-01-21 Achillion Pharmaceuticals, Inc. Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013061285A1 (en) 2011-10-28 2013-05-02 Janssen Pharmaceuticals, Inc Improved process for preparing an intermediate of the macrocyclic protease inhibitor tmc 435
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2970195B1 (en) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
KR20160005686A (ko) 2013-03-15 2016-01-15 아칠리온 파르마세우티칼스 인코포레이티드 소바프레비르 다형체들 및 이의 제조 방법
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US6306987B1 (en) 1997-06-27 2001-10-23 Ciba Specialty Chemicals Corporation Ruthenium and osmium catalysts
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
KR20060008877A (ko) * 2003-04-10 2006-01-27 베링거 인겔하임 인터내셔날 게엠베하 루테늄 착물 촉매 존재하의 복분해 반응에 의한거대사이클릭 화합물의 제조방법
US7148347B2 (en) * 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
ATE500264T1 (de) 2003-09-22 2011-03-15 Boehringer Ingelheim Int Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus

Also Published As

Publication number Publication date
US20080242835A1 (en) 2008-10-02
WO2007030656A8 (en) 2007-07-05
ATE510846T1 (de) 2011-06-15
JP2009509933A (ja) 2009-03-12
JP5190364B2 (ja) 2013-04-24
CA2621360C (en) 2013-12-24
DK1934243T3 (da) 2011-09-05
EP1934243A1 (en) 2008-06-25
US7951773B2 (en) 2011-05-31
EP1934243B1 (en) 2011-05-25
ES2364426T3 (es) 2011-09-02
CA2621360A1 (en) 2007-03-15
WO2007030656A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
PL1934243T3 (pl) Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
WO2004092203A3 (en) Process for preparing macrocyclic compounds
WO2006096652A3 (en) Process for preparing macrocyclic compounds
IL178080A0 (en) Process for preparing macrocyclic compounds
ES2322602T3 (es) Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
PE20060607A1 (es) Derivados de indol tetraciclicos como agentes antivirales
SG163613A1 (en) Macrocyclic inhibitors of hepatitis c virus
NZ588179A (en) Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety
WO2008057871A3 (en) Inhibitors of hepatitis c virus
WO2008057875A3 (en) Inhibitors of hepatitis c virus
NZ586232A (en) HCV protease inhibitors comprising a functionalised proline derivative
WO2008057873A3 (en) Inhibitors of hepatitis c virus
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
NZ595000A (en) Imidazo[4,5-c]pyridine derivative for treating viral infections
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
PE20120993A1 (es) Derivados bifenilicos como antivirales
TW200801044A (en) Macrocylic inhibitors of hepatitis C virus
Wang et al. N-Bromosuccinimide as an oxidant for the transition-metal-free synthesis of 2-aminobenzoxazoles from benzoxazoles and secondary amines
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
TH80266B (th) อนุพันธ์นิวคลีโอไซด์สำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ c
TH73866A (th) วิธีการเตรียมอนุพันธ์ของ 7-(2'-ซับสติติว-เบตา-ไรโบฟูราโนซิล)-4-(NR2R3)-5-(ซับสติติว เอธิน-1-อิล)ไพร์โรโล[2,3-d]ไพริมิดีน
TH124666B (th) สไปโรไซคลิก โพรลีน และการใช้สารเหล่านั้นในการรักษาการติดเชื้อ hcv